Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY: BSX )

101.56 +0.84 (+0.83%)
Official Closing Price Updated: 7:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Which S&P500 stocks are moving on Tuesday?
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Q4 Earnings Roundup: Baxter (NYSE:BAX) And The Rest Of The Medical Devices & Supplies - Diversified Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4,... 
Via StockStory
What Does the Market Think About Boston Scientific?
Via Benzinga
Earnings Scheduled For February 5, 2025
Via Benzinga
Deep Dive Into Boston Scientific Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Q4 Earnings Highs And Lows: Neogen (NASDAQ:NEOG) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQ:NEOG) and its peers. 
Via StockStory
Baxter Earnings: What To Look For From BAX
Healthcare company Baxter International (NYSE:BAX) will be reporting earnings tomorrow morning. Here’s what investors should know. 
Via StockStory
What To Expect From Baxter’s (BAX) Q4 Earnings
Healthcare company Baxter International (NYSE:BAX) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
ResMed Getting Close To Elite Stock Group Entry
ResMed also boasts a 93 Composite Rating. The best growth stocks often have a 90 or higher Composite as they begin their biggest runs. 
Via Investor's Business Daily
Q4 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Boston Scientific (NYSE:BSX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best... 
Via StockStory
$1000 Invested In Boston Scientific 5 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data. 
Via Benzinga
BOSTON SCIENTIFIC CORP (NYSE:BSX) showing some interesting technicals. Here's why.
In-Depth Technical Analysis of BOSTON SCIENTIFIC CORP. 
Via Chartmill
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 billion in sales. 
Via Investor's Business Daily
Boston Scientific Beats Its Own Fourth-Quarter Guidance On Cardiovascular Strength
Boston Scientific stock dipped Wednesday, but the medtech company beat Wall Street's fourth-quarter forecasts. 
Via Investor's Business Daily
Boston Scientific Clocks 22% Jump In Q4 Sales On Strong Heart Devices, Profit And Guidance Exceeds Expectations
Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87. 
Via Benzinga
Zimmer Biomet (ZBH) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
BD (BDX) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be announcing earnings results tomorrow before market open. Here’s what to look for. 
Via StockStory
Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow
Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results tomorrow before the bell. Here’s what to expect. 
Via StockStory
Boston Scientific (NYSE:BSX) Reports Bullish Q4, Guides for Strong Sales Next Quarter
Medical device company Boston Scientific (NYSE:BSX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 22.4% year on year to $4.56 billion. Guidance for next quarter’s... 
Via StockStory
Top 4 Health Care Stocks You May Want To Dump In Q1
Via Benzinga
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
Stock Market Tumbles As Yields Spike; Nvidia, Tesla, Delta, Meta, Jobs Report In Focus: Weekly Review
The S&P 500 and Nasdaq are below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product
The company paused sales of a key product, a rival to Boston Scientific and Medtronic, due to safety concerns. 
Via Investor's Business Daily
Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal
Boston Scientific to acquire Bolt Medical for $600 million upfront plus milestones. Bolt's IVL platform addresses coronary and peripheral artery disease. 
Via Benzinga
Boston Scientific Surges Into Buy Zone On $900 Million Takeover Of Bolt Medical
This was one of the few areas Boston Scientific had a gap in its coronary portfolio, an analyst says. 
Via Investor's Business Daily
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.